Vilerm Drug Interactions

Patients should be monitored closely during Acyclovir-zidovudine combination therapy because it may cause neurotoxicity.
Concomitant administration of Acyclovir and antifungal agent (amphotericin B, ketoconazole) have shown synergistic, therefore the greater antiviral activity of Acyclovir.
Concomitant administration of probenecid and Acyclovir has reportedly increased area under the plasma concentration-time curve (AUC) because inhibition of the renal secretion of Acyclovir by probenecid.
Tablet: Concomitant administration of valproic acid and Acyclovir has decreased valproic acid plasma concentrations and potential increased seizure activity.
Powder for infusion: Acyclovir should be used with caution in patients receiving interferon, the drugs have an additive or synergistic antiviral effect.
IV Acyclovir should be used with caution in patients receiving intrathecal methotrexate.
Increases in plasma of Acyclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are coadministered.
Care is also required (with monitoring for changes in renal function) if administering intravenous Acyclovir with drugs which affect other aspects of renal physiology (e.g. cyclosporin, tacrolimus).